• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2025: $113 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Menu Menu
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

The World Market for Prescription Generic Drugs, 5th Edition

$2,500.00 – $7,000.00

Clear
SKU: KLI1190851 Categories: Pharmaceuticals Market Research, Prescription Drugs Market Reports Pages: 310
  • Description
  • Table of Contents
  • Latest reports

Description

The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol.

This comprehensive study quantifies world markets 2000 to 2010 in the following therapeutic categories: examined at the level of manufacturers’ revenues in each of the following product categories:

  • allergy and respiratory drugs,
  • analgesics (including NSAIDs) and anti-rheumatic drugs,
  • anesthesia,
  • anti-infectives,
  • cancer drugs,
  • cardiovascular drugs,
  • CNS drugs,
  • gastrointestinal drugs,
  • hormone drugs, and
  • ophthalmic drugs.

In addition to market size and growth, market share of leading competitors, the report discusses regulatory, clinical, and business trends and issues in detail, including

  • how the Hatch-Waxman Act works and fails to work,
  • how FDA funding plans will affect filings and approvals in the coming years,
  • what strategies big pharma is using to fend off market share erosion, like autorized generics and aggressive patent filing,
  • how generic biologics fit in the picture,
  • how M&A activity is changing the landscape, and
  • many more

The report also details the big-name drugs set to lose protection over the next 6 years and what level of revenue is at stake for whom.

The report also includes profiles of the top players, including:

  • Actavis Group
  • Altana Pharma AG
  • Andrx Corporation
  • Apotex Group
  • Aurobindo Pharma, Ltd.
  • Barr Laboratories, Inc.
  • Bedford Laboratories
  • Lannett Company, Inc.
  • Mylan Laboratories, Inc.
  • Orchid Chemicals and Pharmaceuticals, Ltd.
  • Par Pharmaceuticals, Inc.
  • Perrigo Company
  • PLIVA Pharmaceuticals, Inc.
  • Ranbaxy Laboratories, Ltd.
  • Roxane Laboratories, Inc.
  • Sandoz International, GmbH
  • Taro Pharmaceutical Industries Ltd.
  • TEVA Pharmaceutical Industries, Ltd.
  • Watson Pharmaceuticals, Inc.
  • United Research Laboratories and Mutual Pharmaceutical Company
  • Zydus Pharmaceuticals, Inc.

Table of Contents

Chapter One: Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Trends Affecting the Market
  • Market Outlook

Chapter Two: Introduction

  • Industry Development
    • Generic Drug Industry Evolution
    • FDA Regulation
    • Development and Approval Process
  • Industry Structure
  • Product Distribution
  • Patent Expirations

Chapter Three: Allergy and Respiratory Drugs

  • Product Categories
    • Asthma, Bronchodilators and Corticosteroids
    • Inhaled Corticosteroids
    • Antiasthmatic Agents
    • Bronchodilating Agents
    • Antihistamines, Decongestants, and Cough Preparations
    • Antihistamines
    • Decongestants
    • Cough Preparations
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs World Market
  • Competitive Analysis

Chapter Four: Analgesics, Nonsteroidal Anti-Inflammatory Drugs, and Antirheumatic Drugs

  • Product Categories
    • Analgesics
    • Nonsteroidal Anti-inflammatory Drugs
    • Antirheumatics
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs World Market
  • Competitive Analysis

Chapter five: Anesthesia Drugs

  • Product Categories
    • General
    • Local
    • Regional
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs World Market
  • Competitive Analysis

Chapter Six: Anti-Infectives

  • Product Categories
    • Systemic Anti-Infectives
    • Topical Anti-Infectives
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs World Market
  • Competitive Analysis

Chapter seven: Cancer Drugs

  • Products
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs World Market
  • Competitive Analysis

Chapter Eight: Cardiovascular Drugs

  • Product Categories
    • Positive Inotropic Agents
    • Antiadrenergics
    • Beta-Adrenergic Blocking Agents
    • Vasodilators
    • Calcium Channel Blockers
    • Angiotensin-Converting Enzyme Inhibitors
    • Antiarrhythmics
    • Antihyperlipidemic Agents
    • Anticoagulants
    • Diuretics
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs. World Market
  • Competitive Analysis

Chapter Nine: Central Nervous System and Psychotherapeutic Drugs

  • Product Categories
    • Antidepressants, Stimulants, and Antipsychotics
    • Antidepressants
    • Stimulants
    • Antipsychotics
    • Anticonvulsants, Antispasmodics, and Muscle Relaxants
    • Anticonvulsants
    • Antispasmodics
    • Muscle Relaxants
    • Parkinson’s Disease, Myasthenia Gravis, and Multiple Sclerosis
    • Parkinson’s Disease
    • Myasthenia Gravis
    • Multiple Sclerosis
    • Sedatives, Hypnotics, and Antianxiety Drugs
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs World Market
  • Competitive Analysis

Chapter Ten: Gastrointestinal Drugs

  • Product Categories
    • Antidiarrheals
    • Antinauseants
    • Antispasmodics
    • Antiulcer
    • Digestants
  • Product News
  • Market Size and Forecast
    • The World Market
    • The U.S. vs the World Market
  • Competitive Analysis

Chapter Eleven: Hormonal Drugs

  • Product Categories
    • Male and Female Hormones
    • Corticosteroids
    • Diabetes Drugs
    • Thyroid Drugs
  • Product News
  • Market Size and Forecast
    • The World Market
    • U.S. vs World Market
  • Competitive Analysis

Chapter Twelve: Ophthalmic Drugs

  • Product Categories
    • Ophthalmic Anti-Infectives
    • Ophthalmic Anti-Inflammatories and Mast Cell Inhibitors
    • Glaucoma Agents
  • Product News
  • Market Size and Forecast
    • The World Market
    • U.S. vs World Market
  • Competitive Analysis

Chapter Thirteen: World Market Summary

  • Overview
  • Total Market Size and Forecast
  • Market and Competitive Analysis

Chapter Fourteen: Issues and Trends

  • Understanding Hatch-Waxman and Its Shortfalls
  • The FDA, Funding and Review Times
  • Big Pharma Tactics—Defensive and Offensive
  • Authorized Generics
  • Generic Biologics
  • Medicaid Generic Drug Reimbursement Issues
  • The Elderly
  • Confusion in Generic Drug Names
  • Broadening Generic Horizons
  • International Generic Drug Issues
  • Industry Consolidation
  • New Generic Giants
  • Patent Issues: Filings and Challenges
  • Patent Reform
  • Generic Growth: Prescriptions, Approvals, Impact
  • Generic Statins Countdown
  • Prescription Drug Costs
  • Generics Improve Compliance
  • Generic Drug Sampling

Chapter Fifteen: Company Profiles

  • Industry Structure and Participants
  • Actavis Group
  • Altana Pharma AG
  • Andrx Corporation
  • Apotex Group
  • Aurobindo Pharma, Ltd
  • Barr Laboratories, Inc.
  • Bedford Laboratories
  • Lannett Company, Inc.
  • Mylan Laboratories, Inc.
  • Orchid Chemicals and Pharmaceuticals, Ltd.
  • Par Pharmaceuticals, Inc.
  • Perrigo Company
  • PLIVA Pharmaceuticals, Inc.
  • Ranbaxy Laboratories, Ltd.
  • Roxane Laboratories, Inc.
  • Sandoz International, GmbH
  • Taro Pharmaceutical Industries Ltd.
  • TEVA Pharmaceutical Industries, Ltd.
  • Watson Pharmaceuticals, Inc.
  • United Research Laboratories and Mutual Pharmaceutical Company
  • Zydus Pharmaceuticals, Inc

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

  • Table 1-1: Market Suumary: World Market for Prescription Generic Drugs Revenues by Segment 2000-2010
  • Figure 1-1: Market Summary: Trending in the World Market for Prescription Generic Drugs by Segment 2000-2010

Chapter Two: Introduction

  • Figure 2-1: Abbreviated New Drug Application Review Flow Chart
  • Table 2-1: Brand Name Companies with Generic Subsidiaries
  • Table 2-2: Number of Best Selling Drugs with Patents Expiring in Years 2006-2012 Grouped by Treatment Category
  • Table 2-3: Best Selling Prescription Drugs with Expected Patent Expirations (Year of Expiration, Brand, Manufacturer, Indication,
  • 2004 Revenues) 2006-2012

Chapter Three: Allergy and Respiratory Drugs

  • Table 3-1: Prescription Allergy and Respiratory ANDA Approvals, 2005
  • Table 3-2: The World Market for Prescription Generic Allergy and Respiratory Drugs by Type 2000-2010
  • Figure 3-1: The World Market for Prescription Generic Allergy and Respiratory Drugs, Revenues by Type 2000-2010
  • Table 3-3: The World Market for Prescription Generic Allergy and Respiratory Drugs, Market Share by Type 2000-2010
  • Table 3-4: The World Market for Prescription Generic Allergy and Respiratory Drugs, U.S. Revenues and Share 2000-2010
  • Figure 3-2: The World Market for Prescription Generic Allergy and Respiratory Drugs, Displaying U.S. Revenues 2000-2010
  • Table 3-5: The World Market for Prescription Generic Allergy and Respiratory Drugs, Revenues and Market Share by Supplier 2005
  • Figure 3-3: The World Market for Prescription Generic Allergy and Respiratory Drugs, Market Share by Leading Supplier 2005

Chapter Four: Analgesics, Nonsteroidal Anti-Inflammatory Drugs, and Antirheumatic Drugs

  • Table 4-1: Prescription Generic Analgesic, NSAID, and Antirheumatic ANDA Approvals, 2005
  • Table 4-2: The World Market for Prescription Generic Analgesics, NSAIDs and Antirheumatic Drugs by Type 2000-2010
  • Figure 4-1: The World Market for Prescription Generic Analgesics, NSAIDs, and Antirheumatic Drugs, Revenues by Type 2000-2010
  • Table 4-3: The World Market for Prescription Generic Analgesics, NSAIDs, and Antirheumatic Drugs, Market Share by Type 2000-2010
  • Table 4-4: The World Market for Prescription Generic Analgesics, NSAIDs, and Antirheumatic Drugs, U.S. Revenues and Share 2000-2010
  • Figure 4-2: The World Market for Prescription Generic Analgesics, NSAIDs, and Antirheumatic Drugs Displaying U.S. Revenues 2000-2010
  • Table 4-5: The World Market for Prescription Generic Analgesics, NSAIDs, and Antirheumatic Drugs Revenues and Market Share by Supplier 2005
  • Figure 4-3: The World Market for Prescription Generic Analgesics, NSAIDs, and Antirheumatic Drugs Market Share by Leading Supplier 2005

Chapter Five: Anesthesia Drugs

  • Table 5-1: Prescription Generic Anesthesia Drug ANDA Approvals, 2005
  • Table 5-2: The World Market for Prescription Generic Anesthesia Drugs 2000-2010
  • Figure 5-1: The World Market for Prescription Generic Anesthesia Drugs Revenues 2000-2010
  • Table 5-3: The World Market for Prescription Generic Anesthesia Drugs, U.S. Revenues and Share 2000-2010
  • Figure 5-2: The World Market for Prescription Generic Anesthesia Drugs Displaying U.S. Revenues 2000-2010
  • Table 5-4: The World Market for Prescription Generic Anesthesia Drugs, Revenues and Market Share by Supplier 2005
  • Figure 5-3: The World Market for Prescription Generic Anesthesia Drugs Market Share by Leading Supplier 2005

CHAPTER Six: Anti-Infectives

  • Table 6-1: Prescription Generic Anti-infective Drug ANDA Approvals, 2005
  • Table 6-2: The World Market for Prescription Generic Anti-Infective Drugs by Type 2000-2010
  • Figure 6-1: The World Market for Prescription Generic Anti-Infective Drugs, Revenues by Type 2000-2010
  • Table 6-3: The World Market for Prescription Generic Anti-Infective Drugs, Market Share by Type 2000-2010
  • Table 6-4: The World Market for Prescription Generic Anti-Infective Drugs U.S. Revenues and Share 2000-2010
  • Figure 6-2: The World Market for Prescription Generic Anti-Infective Drugs Displaying U.S. Revenues 2000-2010
  • Table 6-5: The World Market for Prescription Generic Anti-Infective Drugs, Revenues and Market Share by Supplier 2005
  • Figure 6-3: The World Market for Prescription Generic Anti-Infective Drugs Market Share by Leading Supplier 2005

Chapter Seven: Cancer Drugs

  • Table 7-1: Prescription Generic Cancer Drug ANDA Approvals 2005
  • Table 7-2: The World Market for Prescription Generic Cancer Drugs 2000-2010
  • Figure 7-1: The World Market for Prescription Generic Cancer Drugs Revenues 2000-2010
  • Table 7-3: The World Market for Prescription Generic Cancer Drugs, U.S. Revenues and Share 2000-2010
  • Figure 7-2: The World Market for Prescription Generic Cancer Drugs Displaying U.S. Revenues 2000-2010
  • Table 7-4: The World Market for Prescription Generic Cancer Drugs, Revenues and Market Share by Supplier 2005
  • Figure 7-3: The World Market for Prescription Generic Cancer Drugs Market Share by Leading Supplier 2005

Chapter Eight: Cardiovascular Drugs

  • Table 8-1: Prescription Generic Cardiovascular Drug ANDA
  • Approvals. 2005
  • Table 8-2: The World Market for Prescription Generic Cardiovascular Drugs by Type 2000-2010
  • Figure 8-1: The World Market for Prescription Generic Cardiovascular Drugs Revenues by Type 2000-2010
  • Table 8-3: The World Market for Prescription Generic Cardiovascular Drugs, Market Share by Type 2000-2010
  • Figure 8-2: The World Market for Prescription Generic Cardiovascular Drugs, Share by Type 2005 and 2010
  • Table 8-4: The World Market for Prescription Generic Cardiovascular Drugs U.S. Revenues and Share 2000-2010
  • Figure 8-3: The World Market for Prescription Generic Cardiovascular Drugs Displaying U.S. Revenues 2000-2010
  • Table 8-5: The World Market for Prescription Generic Cardiovascular Drugs, Revenues and Market Share by Supplier 2005
  • Figure 8-4: The World Market for Prescription Generic Cardiovascular Drugs, Market Share by Leading Supplier 2001

Chapter Nine: Central Nervous System and Psychotherapeutic Drugs

  • Table 9-1: Prescription Generic Central Nervous System/Psychotherapeutic Drug ANDA Approvals 2005
  • Table 9-2: The World Market for Prescription Generic Central Nervous System Drugs by Type 2000-2010
  • Figure 9-1: The World Market for Prescription Generic Central Nervous System Drugs Revenues by Type 2000-2010
  • Table 9-3: The World Market for Prescription Generic Central Nervous System Drugs, Market Share by Type 2000-2010
  • Table 9-4: The World Market for Prescription Generic Central Nervous System Drugs, U.S. Revenues and Share 2000-2010
  • Figure 9-2: The World Market for Prescription Generic Central Nervous System Drugs Displaying U.S. Revenues 2000-2010
  • Table 9-5: The World Market for Prescription Generic Central Nervous System Drugs, Revenues and Market Share by Supplier 2005
  • Figure 9-3: The World Market for Prescription Generic Central Nervous System Drugs, Market Share by Leading Supplier 2005

Chapter Ten: Gastrointestinal Drugs

  • Table 10-1: Prescription Generic Gastrointestinal Drug ANDA Approvals 2005
  • Table 10-2: The World Market for Prescription Generic Gastrointestinal Drugs by Type, 2000-2010
  • Figure 10-1: The World Market for Prescription Generic Gastrointestinal Drugs Revenues by Type 2000-2010
  • Table 10-3: The World Market for Prescription Generic Gastrointestinal Drugs, Market Share by Type 2000-2010
  • Figure 10-2: The World Market for Prescription Generic Gastrointestinal Drugs, Share by Type 2005 and 2010
  • Table 10-4: The World Market for Prescription Generic Gastrointestinal Drugs, U.S. Revenues and Share 2000-2010
  • Figure 10-3: The World Market for Prescription Generic Gastrointestinal Drugs, Displaying U.S. Revenues 2000-2010
  • Table 10-5: The World Market for Prescription Generic Gastrointestinal Drugs, Revenues and Market Share by Supplier 2005
  • Figure 10-4: The World Market for Prescription Generic Gastrointestinal Drugs, Market Share by Leading Supplier 2005

Chapter Eleven: Hormonal Drugs

  • Table 11-1: Prescription Generic Hormone Drug ANDA Approvals 2005
  • Table 11-2: The World Market for Prescription Generic Hormone Drugs by Type 2000-2010
  • Figure 11-1: The World Market for Prescription Generic Hormone Drugs Revenues by Type 2000-2010
  • Table 11-3: The World Market for Prescription Generic Hormone Drugs, Market Share by Type 2000-2010
  • Figure 11-2: The World Market for Prescription Generic Hormone Drugs Share by Type 2005 and 2010
  • Table 11-4: The World Market for Prescription Generic Hormone Drugs U.S. Revenues and Share 2000-2010
  • Figure 11-3: The World Market for Prescription Generic Hormone Drugs Displaying U.S. Revenues 2000-2010
  • Table 11-5: The World Market for Prescription Generic Hormone Drugs, Revenues and Market Share by Supplier 2005
  • Figure 11-4: The World Market for Prescription Generic Hormone Drugs Market Share by Leading Supplier 2005

Chapter Twelve: Ophthalmic Drugs

  • Table 12-1: Prescription Generic Ophthalmic Drug ANDA Approvals 2001
  • Table 12-2: The World Market for Prescription Generic Ophthalmic Drugs by Type 2000-2010
  • Figure 12-1: The World Market for Prescription Generic Ophthalmic Drugs Revenues by Type 2000-2010
  • Table 12-3: The World Market for Prescription Generic Ophthalmic Drugs, Market Share by Type 2000-2010
  • Table 12-4: The World Market for Prescription Generic Ophthalmic Drugs, U.S. Revenues and Share 2000-2010
  • Figure 12-2: The World Market for Prescription Generic Ophthalmic Drugs Displaying U.S. Revenues 2000-2010
  • Table 12-5: The World Market for Prescription Generic Ophthalmic Drugs, Revenues and Market Share by Supplier 2005
  • Figure 12-3: The World Market for Prescription Generic Ophthalmic Drugs Market Share by Leading Supplier 2005

Chapter Thirteen: World Market Summary

  • Table 13-1: The World Market for Prescription Generic Drugs Revenues by Segment 2000-2010
  • Figure 13-1: The World Market for Prescription Generic Drugs Revenues by Segment 2000-2010
  • Figure 13-2: The World Market for Generic Drugs Market Share by Type 2005 and 2010
  • Table 13-3: World Market for Prescription Generic Drugs Revenues and Segments of Participation by Leading Player 2005

Chapter Fourteen: Issues and Trends

  • Table 14-1: Reorganization of Major Japanese Generic Drug Manufacturers

 

    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    Drug Delivery Technology and Applications: A summary of Kalorama’s market research, 2001-2003

    $746.00 – $1,492.00
  • Placeholder image

    Type II Diabetes: The 45 Market in the United States for Drugs and Diagnostics

    $2,995.00 – $5,990.00
  • Placeholder image

    Medicare Reform and the Pharmaceutical Industry: Implications of the Medicare Prescription Drug Improvement and Modernization Act of 2003

    $795.00 – $1,590.00
  • Placeholder image

    World Market for Anti-infectives Volume II: The World Market for Antibacterial Medications, The

    $2,500.00 – $5,000.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • What Is the Size of the IVD Market in 2025? September 8, 2025
  • Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain  June 24, 2025
  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
The U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Pr...Medical and Biological Sensors and Sensor Systems – Markets, Applications,...
Scroll to top